Skip to main content

Table 2 Changes in cognitive and functional abilities during three years of ChEI treatment in mild AD

From: Progression of mild Alzheimer’s disease: knowledge and prediction models required for future treatment strategies

Variable 2 months 6 months 12 months 18 months 24 months 30 months 36 months
  (n= 706) (n= 662) (n= 597) (n= 521) (n= 450) (n= 374) (n= 306)
Completion rate (%) 96.2 90.2 81.3 71.0 61.3 51.0 41.7
MMSE scorea 24.0 (23.8, 24.2) 23.5 (23.3, 23.8) 22.8 (22.5, 23.2) 22.1 (21.7, 22.5) 21.4 (20.9, 21.8) 21.1 (20.5, 21.6) 20.6 (20.0, 21.2)
ADAS-cog (0 to 70) scorea   17.4 (16.8, 18.0) 18.3 (17.6, 19.0) 19.5 (18.6, 20.3) 20.1 (19.1, 21.1) 21.3 (20.0, 22.7) 21.7 (20.2, 23.2)
IADL scorea   15.8 (15.4, 16.2) 17.0 (16.6, 17.5) 17.9 (17.4, 18.5) 18.8 (18.2, 19.4) 19.4 (18.7, 20.1) 19.8 (19.1, 20.6)
MMSE score, change from baselinea 0.61 (0.43, 0.78) 0.19 (−0.04, 0.42) −0.57 (−0.86, −0.28) −1.31 (−1.66, −0.96) −2.20 (−2.64, −1.77) −2.54 (−3.06, −2.02) −3.10 (−3.66, −2.54)
ADAS-cog (0 to 70) score, change from baselinea   −0.15 (−0.65, 0.34) −1.20 (−1.77, −0.63) −2.58 (−3.27, −1.90) −3.81 (−4.59, −3.03) −4.97 (−6.09, −3.85) −6.12 (−7.35, −4.89)
IADL score, change from baselinea   −1.12 (−1.34, −0.91) −2.48 (−2.78, −2.17) −3.64 (−4.01, −3.26) −4.75 (−5.18, −4.33) −5.54 (−6.06, −5.02) −6.27 (−6.86, −5.68)
MMSE score, improved/unchanged patients (%) 72.7 64.1 55.0 46.9 41.9 38.2 33.0
ADAS-cog (0 to 70) score, improved/unchanged patients (%)   55.3 48.8 41.8 36.7 32.9 31.1
IADL score, improved/unchanged patients (%)   49.7 34.2 24.3 18.0 14.8 13.8
  1. aMean (95% confidence interval).
  2. For clarity, clinical improvements for all scales have been tabulated as positive changes from the start of ChEI treatment (baseline).
  3. ADAS-cog, Alzheimer’s Disease Assessment Scale-cognitive subscale; ChEI, cholinesterase inhibitor; IADL, Instrumental Activities of Daily Living scale; MMSE, Mini-Mental State Examination.